Citation: davtyan et al.Melody endocarditis does not equal valve removal: variations in practice in a multicenter experience.Pediatr cardiol.2020, 41:1248¿1298.Pics-aics 2020-pediatric and adult interventional cardiac symposium from 8 sep 2020 thru 11 sep 2020.Earliest date of conference used for date of event.No unique device identifier (serial/lot) numbers were provided; without this information it could not be determined whether these observations have been previously reported.Without return of the product no definitive conclusion can be made regarding the clinical observations.If information is provided in the future, a supplemental report will be issued.
|
Medtronic received information via literature regarding antibiotic therapy for endocarditis following implant of a melody bioprosthetic valve.All data were collected from four united states centers from 2010 to 2019.The study population included 666 patients (demographic information not provided), all of which were implanted with a medtronic melody bioprosthetic valve (unique device identifier numbers not provided).During a mean follow-up period of 2.9 years, 61 patients had endocarditis and 33 of those patients were treated medicinally with success.Two patients had recurrent endocarditis, one of which was treated medicinally and one which required surgery to explant the valve.Other valve explants were performed due to stenosis with or without right ventricular dysfunction, concern for inadequate response to antibiotics, and surgeon preference.Based on the available information medtronic product may have been associated with the adverse event(s).No additional adverse patient effects or product performance issues were reported.
|